Use of Ceftaroline in Hospitalized Patients with and without COVID-19: A Descriptive Cross-Sectional Study

Daniele Roberto Giacobbe(Ospedale Policlinico San Martino), Matteo Bassetti(University of Udine), Marco Berruti(University of Genoa), Silvia Dettori(Ospedale Policlinico San Martino), Chiara Dentone(Ospedale di Sanremo), Mauro Giacomini(University of Genoa), Sara Mora(University of Genoa), Michele Mirabella(Ospedale Policlinico San Martino), Federica Briano(University of Genoa), Federica Portunato(Ospedale Policlinico San Martino), Chiara Russo(University of Genoa), Veronica Martini(University of Genoa)
Antibiotics
June 23, 2021
10.3390/antibiotics10070763
Cited by 9

Related Papers

Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium
|Clinical Infectious Diseases|2019|2.8k
Effect of Piperacillin-Tazobactam vs Meropenem on 30-Day Mortality for Patients With <i>E coli</i> or <i>Klebsiella pneumoniae</i> Bloodstream Infection and Ceftriaxone Resistance
|JAMA|2018|761
How to manage Pseudomonas aeruginosa infections
|Drugs in Context|2018|743
Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: a meta-analysis of individual participant data
|The Lancet Respiratory Medicine|2014|648
Efficacy of Ceftazidime-Avibactam Salvage Therapy in Patients With Infections Caused by<i>Klebsiella pneumoniae</i>Carbapenemase–producing<i>K. pneumoniae</i>
|Clinical Infectious Diseases|2018|351